Call 800 665 0411 to learn about our services for your stock

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS

Share on StockTwits

CSE New Medical Tech Listing - Diagnamed Holdings Corp. (CSE: DMED)


November 7, 2022 ( Newswire) The common shares of Diagnamed Holdings Corp. have been approved for listing on the CSE.

Listing and disclosure documents will be available at on the trading date.

Diagnamed Holdings Corp. is a developing a platform of software-based prescription digital therapeutic products ("PDT Products") with the potential to improve early detection of neurological disorders, overall patient health and lower healthcare costs. The Company's PDT Products include: (1) BrainYear™, an electroencephalogram-based ("EEG") machine-learning solution to detect an individual's brain age for use in clinic and at-home; and (2) BrainTremor™, a wearable device to detect tremors and brain activity for neurological disorders by EEG. The Company is conducting research and development of digital therapeutics applications with the intent to commercialize its PDT Products in the United States and currently outsources its research and development in the U.S. and Canada. The Company's goal is to complete the development of a prototype of BrainYear™ and BrainTremor™ for clinical research, and ultimately commercialize these products initially in the United States.


Les actions ordinaires de Diagnamed Holdings Corp. ont ete approuvees pour inscription à la CSE.

Les documents d'inscription et d'information seront disponibles sur a la date de negociation.

Diagnamed Holdings Corp. developpe une plate-forme de produits therapeutiques numeriques sur ordonnance (« Produits PDT ») avec le potentiel d'ameliorer la detection precoce des troubles neurologiques, la sante globale des patients et de reduire les coûts des soins de sante. Les produits PDT de la Societe comprennent : (1) BrainYear™, une solution d'apprentissage automatique basee sur l'electroencephalogramme (« EEG ») pour detecter l'âge du cerveau d'un individu à utiliser en clinique et à domicile ; et (2) BrainTremor™, un dispositif portable pour detecter les tremblements et l'activite cerebrale pour les troubles neurologiques par EEG. La Societe mène des activites de recherche et de developpement d'applications therapeutiques numeriques dans le but de commercialiser ses produits PDT aux etats-Unis et externalise actuellement sa recherche et son developpement aux etats-Unis et au Canada. L'objectif de la Societe est d'achever le developpement d'un prototype de BrainYear™ et BrainTremor™ pour la recherche clinique, et finalement de commercialiser ces produits initialement aux etats-Unis.

The Exchange is accepting Market Maker applications for DMED. Please email:

If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail:

Pour toute question, pour obtenir de l'information supplementaire veuillez communiquer avec le service des inscriptions au 416 367-7340 ou par courriel a l'adresse: is a Canadian Securities Exchange (CSE) Service Provider; Cannabis stocks, Blockchain stocks, Mining, E-sports, Energy, Biotech and more...

Check out listing on the CSE service provider list. We offer discounts to CSE listed stocks!

The Canadian Securities Exchange, or CSE, is operated by CNSX Markets Inc. Recognized as a stock exchange in 2004; the CSE began operations in 2003 to provide a modern and efficient alternative for companies looking to access the Canadian public capital markets.

More Info:

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: Learn more about publishing your news release and our other news services on the newswire

Global investors must adhere to regulations of each country. Please read privacy policy: - A Leading Global Investor Website for Biotech Industry Stocks - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

Buy a biotech guest post on